Latest News

Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

CAMBRIDGE, Mass. & SAN CARLOS, Calif.–(BUSINESS WIRE)– #KRASmutation–Elicio Therapeutics, a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma (PDAC) who have undergone neoadjuvant chemotherapy followed by pancr

Source link

Related posts

Chinese Scientists Make Monkeys Smarter By Adding Human Brain Genes


Workshop explores the future of artificial intelligence in medical imaging


Dunkin’ Donuts Customers Urged To Get Hepatitis A Vaccine After Employee Tested Positive


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy